Compare · FONR vs MDT
FONR vs MDT
Side-by-side comparison of Fonar Corporation (FONR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FONR and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $138.66B, about 1356.4x FONR ($102.2M).
- Over the past year, FONR is up 55.7% and MDT is down 0.8% - FONR leads by 56.5 points.
- MDT has been more active in the news (6 items in the past 4 weeks vs 3 for FONR).
- MDT has more recent analyst coverage (25 ratings vs 0 for FONR).
- Company
- Fonar Corporation
- Medtronic plc.
- Price
- -
- -
- Market cap
- $102.2M
- $138.66B
- 1M return
- +1.54%
- -5.21%
- 1Y return
- +55.66%
- -0.81%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 1981
- News (4w)
- 3
- 6
- Recent ratings
- 0
- 25
Fonar Corporation
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest FONR
- Amendment: SEC Form SC 13E3/A filed by Fonar Corporation
- SEC Form DEFM14A filed by Fonar Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Fonar Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Fonar Corporation
- Amendment: SEC Form SC 13E3/A filed by Fonar Corporation
- SEC Form PRER14A filed by Fonar Corporation
- SEC Form SC 13E3 filed by Fonar Corporation
- SEC Form PREM14A filed by Fonar Corporation
- SEC Form DEFA14A filed by Fonar Corporation
- Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
Latest MDT
- Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2026
- Telix Strengthens Board with Additional Director Appointments
- Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.
- Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
- Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure
- Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing